Research review priorities
Supplement research priorities
These are research priorities, not recommendations. We selected decisions where public interest, plausible benefit, evidence maturity, and safety stakes make a careful synthesis especially useful.
- priority dossiers
- 148
- claim-level questions
- 444
- study extraction underway
- 148
01 / PRIORITY
How priorities were selected
Priority reflects relevance to healthy aging, frequency of real-world use, maturity of human evidence, the cost of a wrong decision, and the need to separate a valid narrow use from broader marketing claims. It does not rank efficacy or imply that everyone should take the product.
02 / EXTRACTION
What happens next
For every question, we screen the PubMed candidate set, connect multiple publications from the same trial, extract population, dose, comparator, duration, outcomes, harms, and funding, then synthesize supportive, mixed, negative, and safety findings together.
Only screened studies enter audited study and participant totals. Search-result counts and the papers listed here as questions never become evidence by themselves.Bacopa monnieri
- Review stage
- Extracting studies
- audited research papers
- 2
Why this is a research priority
Older small trials suggest a memory-specific signal, while a newer industry-linked trial found no primary cognitive benefit and more minor adverse effects.
Questions being reviewed
- Does Bacopa improve prespecified memory outcomes in adequately powered, independently replicated trials?
- Does it improve attention, working memory, or everyday function rather than selected free-recall tests?
- Which standardized extract, dose, duration, digestive effects, headache, interactions, and pregnancy limits apply?
Ginkgo biloba
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
A large Cochrane review found little or no benefit in mild cognitive impairment and only low-certainty, heterogeneous short-term benefit in dementia.
Questions being reviewed
- How do effects differ between subjective complaints, mild cognitive impairment, and diagnosed dementia?
- Are changes in cognition, global status, or daily function clinically meaningful and sustained beyond six months?
- Which standardized extract, bleeding, seizure, surgery, medicine-interaction, and product-quality limits apply?
Citicoline (CDP-choline)
- Review stage
- Extracting studies
- audited research papers
- 2
Why this is a research priority
A small manufacturer-linked aging trial found selected secondary memory benefits, while a large acute-stroke trial found no recovery benefit.
Questions being reviewed
- Does citicoline improve prespecified memory and everyday function in independently replicated aging trials?
- Which neurological indications, if any, show clinical recovery rather than biomarker changes?
- Which dose, formulation, duration, medicine interactions, and industry-independence limits apply?
Phosphatidylserine
- Review stage
- Extracting studies
- audited research papers
- 2
Why this is a research priority
Older bovine-derived positive evidence does not transfer to modern soy products, and a directly relevant soy trial was negative.
Questions being reviewed
- Does modern soy- or sunflower-derived phosphatidylserine improve prespecified memory or cognition versus placebo?
- Why are bovine-cortex, soy, sunflower, and multi-ingredient products not interchangeable?
- What dose, duration, allergy, anticoagulant, medicine, and long-term safety limits apply?
Myo-inositol
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
The international PCOS guideline review found only limited and inconclusive evidence despite possible metabolic benefits.
Questions being reviewed
- Which metabolic, hormonal, menstrual, and reproductive PCOS outcomes improve with myo-inositol?
- How does myo-inositol compare with placebo, metformin, fertility care, and combination products?
- What dose, ratio, gastrointestinal, pregnancy, diabetes-treatment, and shared-care limits apply?
03 / SOURCES
Research standards
The review begins with federal evidence summaries and PubMed records, then moves to trial-level extraction. Product claims or another publisher’s evidence grade are not copied into the ledger.